Home / Resource Library / Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

Long term follow up of a phase I trial investigating CAR-T zamtocabtagene autoleucel in relapsed lymphomas.